Zai Lab Ltd.

Zai Lab Ltd. is a biopharmaceutical company, which engages in the developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. Its products include Zejula, Optune, Qinlock, and Nuzyra. The company was founded by Samantha Ying Du and Marietta Wu in April 2014 and is headquartered in Shanghai, China.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Zai Lab Limited (NASDAQ: ZLAB) resulting from allegations that Zai Lab may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Zai Lab securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The.

EQUITY ALERT: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Zai Lab Limited Investors with Losses to Inquire About Securities Class Action Investigation – ZLAB

Zai Lab collaborated with NovoCure on a study to treat non-small cell lung cancer. There were some concerns about the validity of the study.

Why Shares of Zai Lab Are Dropping Wednesday

LOS ANGELES--(BUSINESS WIRE)---- $ZLAB #ZLAB--The Schall Law Firm Announces it is Investigating Claims Against Zai Lab Limited and Encourages Investors with Losses to Contact the Firm.

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Zai Lab Limited and Encourages Investors with Losses to Contact the Firm

Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities

Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

Three poster presentations to provide updates on Zai Lab's oncology programs focused on unresectable solid tumors, ovarian cancer and gastrointestinal stromal tumors

Zai Lab to Highlight New Data from its Oncology Pipeline at 2023 ASCO Annual Meeting

SHANGHAI, China and CAMBRIDGE, Mass., May 25, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the company's senior management team will participate in the following investor conferences in June 2023:

Zai Lab Announces Participation in June Investor Conferences

Alibaba

Pinduoduo Inc - ADR

Many Wall Street analysts still see an economic recovery playing out in China. President Biden recently said he expects relations with China to improve "very shortly.

Why Shares of Alibaba, PDD, and Zai Lab Are Rising Today

SHANGHAI, China and CAMBRIDGE, Mass., May 18, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted priority review to repotrectinib for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small-cell lung cancer (NSCLC).

Zai Lab Announces That Repotrectinib Granted Priority Review by China's NMPA

Zai Lab Limited. (NASDAQ:ZLAB ) Q1 2023 Earnings Conference Call May 10, 2023 8:00 AM ET Company Participants Billy Cho - Chief Financial Officer Samantha Du - Founder, Chairperson and Chief Executive Officer Josh Smiley - Chief Operating Officer Rafael Amado - President, Head of Global Oncology Research and Development Harald Reinhart - President, Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases Jonathan Wang - Chief Business Development Conference Call Participants Michael Yee - Jefferies Yigal Nochomovitz - Citi Group Jonathan Chang - SVB Securities Ziyi Chen - Goldman Sachs Seamus Fernandez - Guggenheim Securities Yang Huang - Credit Suisse Rebecca Liang - Bernstein Operator Hello, ladies and gentlemen.

Zai Lab Limited (ZLAB) Q1 2023 Earnings Call Transcript

SHANGHAI and CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the first quarter of 2023, along with recent product highlights and corporate updates.

Zai Lab Announces First Quarter 2023 Financial Results and Corporate Updates

YL212 expands Zai Lab's lung cancer franchise and enriches its global oncology pipeline with a potential first-in-class ADC YL212 expands Zai Lab's lung cancer franchise and enriches its global oncology pipeline with a potential first-in-class ADC

Zai Lab Announces Strategic Partnership and Global License Agreement with MediLink Therapeutics for a Next Generation Antibody-Drug Conjugate Program in Oncology

SHANGHAI and CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) today announced that the results of the LUNAR phase 3 clinical trial in metastatic, non-small cell lung cancer (NSCLC) will be presented for the first time at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, to be held from June 2 to June 6.

Zai Lab Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Company to Host Conference Call and Webcast on May 10, 2023, at 8:00 a.m. ET Company to Host Conference Call and Webcast on May 10, 2023, at 8:00 a.m. ET

Zai Lab to Announce First Quarter 2023 Financial Results and Corporate Updates on May 9, 2023

New translational and clinical biomarker data from Zai Lab's global oncology program ZL-1211 will be featured in a poster presentation (Abstract presentation number: 4531) New translational and clinical biomarker data from Zai Lab's global oncology program ZL-1211 will be featured in a poster presentation (Abstract presentation number: 4531)

Zai Lab to Highlight New Data from its Oncology Portfolio at 2023 AACR Annual Meeting

Zai Lab will soon launch a handful of new medicines in China. It's also seeking approval for many of its therapies in the U.S. The company also has enough cash to survive even if some of its clinical trials fail.

1 Hot Growth Stock to Buy Hand Over Fist Before It Blasts Off

Third positive registrational trial met its primary endpoint, with KarXT demonstrating an 8.4-point reduction in PANSS total score compared to placebo at Week 5 (p

Zai Lab Partner Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia

Precigen

When biotechs launch drugs or report on clinical trials, their shares can jump in a big way. Precigen's technology could make it a leader in low-cost immunotherapies.

2 Unmatched Stocks Wall Street Thinks Will Soar 152% or More in the Next 2 Years

Novocure

The bear market has been brutal to small and unprofitable biopharma stocks. Zai Lab plans to commercialize a baffling number of its programs, and soon.

2 Stocks That Could Rebound and Rise 30% or More in 2023

Zai lab's diversified pipeline, strong partnerships, and proven track record of successful drug development make it an attractive investment opportunity in the biotech industry. The recent acceptance of the New Drug Application for sulbactam-durlobactam by the NMPA in China demonstrates a path going forward for the drug.

Zai Lab: Positioned For Growth In The Oncology Treatment Market

The consensus price target hints at an 115.3% upside potential for Zai Lab Limited Unsponsored ADR (ZLAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Does Zai Lab Limited Unsponsored ADR (ZLAB) Have the Potential to Rally 115.25% as Wall Street Analysts Expect?

COMPASS Pathways

Biotech stocks are risky, but high-potential plays can pay off big. Compass Pathways is making progress towards commercializing its first therapy.

2 Growth Stocks With Incredible Potential in the Next 5 Years

Zai Lab Limited (NASDAQ:ZLAB ) Q4 2022 Earnings Conference Call March 2, 2023 8:00 AM ET Company Participants Billy Cho - Chief Financial Officer Samantha Du - Founder, Chairperson and Chief Executive Officer Josh Smiley - Chief Operating Officer Rafael Amado - President, Head of Global Oncology Research and Development Harald Reinhart - President, Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases Jonathan Wang - Chief Business Development Conference Call Participants Michael Yee - Jefferies Anupam Rama - J.P. Morgan Yigal Nochomovitz - Citi Jonathan Chang - SVB Leerink Ziyi Chen - Goldman Sachs Seamus Fernandez - Guggenheim Partners Yang Huang - Credit Suisse Operator Hello, ladies and gentlemen.

Zai Lab Limited (ZLAB) Q4 2022 Earnings Call Transcript

SHANGHAI and CAMBRIDGE, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced full-year 2022 financial results, along with recent product highlights and corporate updates.

Zai Lab Announces Full-Year 2022 Financial Results and Recent Corporate Updates

SHANGHAI and CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), today announced that members of the company's senior management team will participate in the following investor conferences in March 2023:

Zai Lab Announces Participation in March Investor Conferences

SHANGHAI, China and CAMBRIDGE, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) will present two oral presentations highlighting the ad hoc interim overall survival (OS) study results of ZEJULA® (niraparib) from the NORA Phase 3 study and a post hoc analysis from the Phase 3 PRIME trial of niraparib maintenance therapy at the upcoming European Society for Medical Oncology (ESMO) Gynaecological Cancers Congress on February 23-24, 2023.

News for Zai Lab Ltd. Stock (ZLAB)